Navigation Links
Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Date:5/22/2012

BOONTON, N.J., May 22, 2012 /PRNewswire/ -- Unigene Laboratories, Inc. (OTCBB: UGNE) a leader in the design, delivery, manufacture and development of peptide-based therapeutics today reported positive data from recently completed preclinical studies in rats and dogs for its lead proprietary anorexigenic peptide, UGP281. 

UGP281, a potent anorexigenic peptide selectively targeting the amylin receptor, is under development by Unigene for the treatment of morbid obesity.  In multiple-dose pharmacology studies in rats and beagle dogs, UGP281, administered subcutaneously, produced a dose-related decrease in body weight of 10-15% over a 7-day treatment period.  The reduction in food intake was acute and dramatic, falling close to zero at relatively low doses, and was consistent with the targeted pharmacology.  Changes in body weight throughout the studies were tightly aligned with decreases in food consumption.  UGP281 was well tolerated with no overt adverse findings in the studies conducted to date, and its therapeutic window appeared to be substantial. 

These data compare favorably to what has been described preclinically with other weight loss compounds currently, or previously, under development.  Additionally, since UGP281 does not bind to serotonin receptors, the risk of unwanted cardiovascular effects is expected to be significantly less as compared to other obesity product candidates.

Furthermore, as successfully demonstrated in previous preclinical studies, UGP281 has the potential to be dosed orally and manufactured recombinantly by way of Unigene's Peptelligence™ technology platform.

Frank L. Greenway, MD, Professor and Director of Outpatient Clinical Research, Pennington Biomedical, Baton Rouge, LA, commented, "The preclinical data seen with Unigene's peptide, UGP281 are very exciting.  The robust effects on food consumption and body weight loss demonstrated in the rece
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
3. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
4. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
7. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
8. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
9. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
10. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
11. Fujifilm Demonstrates the Latest Advancements of Synapse® PACS at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 AcelRx Pharmaceuticals, Inc. (Nasdaq: ... the development and commercialization of innovative therapies for the ... and reported financial results for the three and six ... include: , On July 23, 2015, the Committee ... positive opinion for Zalviso™ for the management of acute ...
(Date:8/3/2015)... CHICAGO , August 3, 2015 ... Report 2015 market research with 2020 forecasts as ... the healthcare and medical devices intelligence collection of ... medical simulation market with 2020 forecasts spread across ... supported with 170 tables and figures is now ...
(Date:8/3/2015)... 2015  Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" ... (NASDAQ: HZNP ) ("Horizon") announcement that it intends ... set a record date to determine the shareholders eligible ... Depomed Board will review the request when it is ... contains the information required under Depomed,s bylaws, the Depomed ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 2AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 3AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 4AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 5AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 6AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 7AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 8AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 9AcelRx Pharmaceuticals Provides Business Update and Reports Second Quarter and Six Months 2015 Financial Results 10Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6
... NASHUA, N.H., June 19 iCAD, Inc. (Nasdaq:,ICAD), ... the early identification of cancer, today announced it ... virtual colonoscopy CAD,product, in partnership with ACR Image ... (ACR). iCAD and ACR Image Metrix, having completed ...
... Difficult-to-Treat Skin ... methicillin-resistant Staphylococcus aureus (MRSA), ... FRX ) today announced positive results from two ... with activity against gram-positive bacteria, such as MRSA,and gram ...
Cached Medicine Technology:iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 2iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 3iCAD Initiates Clinical Study of Its Virtual Colonoscopy CAD in Partnership with ACR Image Metrix 4Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections 2Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections 3Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections 4
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... as one of 20 finalists for America’s Favorite Veterinarian. The contest is put ... by a judging committee from 500 nominees. Nominees were evaluated on community involvement, ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... of higher learning, announced today that its RN to BSN and Master ... been awarded full accreditation through June 2020 from the Commission on Collegiate ...
(Date:8/4/2015)... ... 04, 2015 , ... Continuing Education Company (CEC) ... interaction simulation session entitled "NOACS: What the Evidence Shows in Managing AFib, ... Inc. and EDUmotion US LLC. , This special activity was recently presented during ...
(Date:8/4/2015)... ... 2015 , ... IN AMERICA and the program's host, James ... affects millions of Americans every single year. To help people obtain a better ... the latest segment produced with the assistance of several top medical professionals. ...
(Date:8/4/2015)... ... 04, 2015 , ... Healthcare IT News (HITN), ... in healthcare and technology markets, today announced significant spikes in website traffic and ... Health Record (EHR) decision. The DOD related numbers solidify HITN’s status as the ...
Breaking Medicine News(10 mins):Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 2Health News:Dr. Gary Richter, Oakland Holistic Veterinarian, Among 20 Finalists for America’s Favorite Veterinarian 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 2Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 3Health News:Loyola University New Orleans Awarded Accreditation for its Online RN to BSN and MSN Programs 4Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:Coverage of DOD’s EHR Decision Reinforces Healthcare IT News’ Leadership 2
... study shows that arthritis in the knee is linked to ... than the other. Whether or not leg length differential is ... findings may allow people to take preventive measures before the ... for treatment may be possible, says Derek Cooke, Queen,s University ...
... ... consumer E-commerce site offering wholesale prices on over 15.000 organic and natural items. Using the ... club becomes the first organic and natural online retailer to do this with a large ... (PRWEB) March ...
... medication cuts cancer risk , WEDNESDAY, March 31 (HealthDay News) ... to fight the problems of an enlarged prostate gland can ... a debate that started with an earlier study of a ... April 1 issue of the New England Journal of ...
... dying needed someone else to make decisions, research finds , ... directives, such as a living will or a durable power ... of medical care that they,ve requested as they near the ... study also found that 30 percent of people required another ...
... part or all of their stomach removed, the hormone ... according to a new study in Gastroenterology , ... Institute. "It is our obligation to invent novel ... study provides convincing data for the beneficial effects of ...
... A new study conducted by Italian researchers, in collaboration ... that biofeedback is more effective than two other treatments for ... "The importance of this work is that chronic rectal ... treat nothing seems to work for more than a ...
Cached Medicine News:Health News:Organic Wholesale Club Brings Wholesale Club Concept to Large Organic and Natural E-commerce Site 2Health News:Study Revives Debate on Prostate Drug 2Health News:Study Revives Debate on Prostate Drug 3Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 2Health News:Advance Directives Help Assure End-of-Life Wishes Are Honored 3Health News:Promising hormone may help reduce malnutrition in gastric cancer patients 2Health News:Biofeedback more effective than EGS and massage for chronic rectal pain 2
The CA method used on the Dade Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of calcium in serum....
For the quantitative in vitro determination of Total Protein in serum and plasma...
The LDH method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of lactate dehydrogenase activity in serum or plasma...
For the quantitative in vitro determination of Anti-Streptolysin-O (ASO) in serum....
Medicine Products: